Skip to main content

prostate cancer Archives

Polygenic “scores” may improve cancer screening

Oct. 31, 2023—Accounting for genetic variability in biomarkers not associated with cancer risk could avoid unnecessary diagnostic procedures, Vanderbilt researchers found.

Read more


International workgroup of geneticists issues CHEK2 guidelines

Jul. 26, 2023—International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.

Read more


More U.S. prostate cancer patients choosing active surveillance

Apr. 3, 2023—A Vanderbilt study found the number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable intermediate-risk cancers.

Read more


Study evaluates polygenic risk score for prostate cancer risk prediction

Mar. 16, 2023—A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

Read more


Study reveals pathways for aggressive prostate cancer subtype

Oct. 27, 2022—Research from Vanderbilt-Ingram Cancer Center has revealed new information about the molecular pathways of cribriform prostate cancer.

Read more


Clinic helps patients prepare to move beyond prostate cancer

Aug. 4, 2022—Vanderbilt's REACH for Survivorship Clinic takes a holistic approach to help treat prostate cancer patients.

Read more


Prostate cancer treatment regret

Dec. 9, 2021—Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

Read more


Combo therapy slows prostate cancer

Oct. 19, 2021—A new combination treatment showed promise in slowing the growth of castration-resistant prostate cancer in animal models, Vanderbilt researchers discovered.

Read more


Clinical trial tests ATR inhibitor in difficult-to-treat cancers

Sep. 23, 2021—  by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...

Read more


Treating metastatic prostate cancer

Jun. 22, 2021—An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.

Read more


Prostate cancer microenvironment

Mar. 23, 2021—Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

Read more


New predictors of prostate cancer risk

Sep. 17, 2020—An international group of researchers including Vanderbilt epidemiologists has identified new DNA methylation biomarkers associated with prostate cancer risk.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more